Although the elevated level of IL-10 over IL-12 suggests the predomination of Th2 response during the treatment, further studies are necessary to exactly determine the type of cells that adopts such a behavior in response to treatment with calcitriol and its analogs during tumor progression. This evidence concerns the gene IL10 and neoplasm.